Summary
This Nature study presents a deep genomic chronology of circulating tumour DNA in men with treatment-resistant prostate cancer, using whole-genome sequencing to track clonal evolution and identify mutations associated with therapeutic resistance. The work, conducted by the SU2C/PCF West Coast Prostate Cancer Dream Team, appears to establish ctDNA profiling as a means of understanding the dynamic genomic landscape driving resistance to standard treatments. The findings may inform stratification and monitoring of advanced prostate cancer patients, though applicability to prevention or nutritional intervention is limited.
UK applicability
This research is relevant to UK oncology and precision medicine strategies, particularly the NHS's adoption of genomic diagnostics in cancer care and treatment selection for metastatic prostate cancer. However, the findings are primarily applicable to clinical management of advanced disease rather than prevention or primary care.
Key measures
Whole-genome sequencing of circulating tumour DNA; clonal architecture; treatment-resistance mutations; temporal evolution of genomic variants
Outcomes reported
The study characterised circulating tumour DNA (ctDNA) dynamics and clonal evolution in treatment-resistant prostate cancer patients over time using whole-genome sequencing. The research traced genomic changes associated with resistance to androgen-deprivation and other therapeutic interventions.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.